And so both government patients and private insurance patients are being accepted and getting through process.
Q – Unidentified Analyst: Thank you.
Operator: Thank you. One moment for our next question. And our next question comes from Gil Blum Needham.
Q – Unidentified Analyst: Hi. This is Ethan [ph] on for Gil. Thank you for taking our question. Moving to Fabry for a second. How important do you think your partnership with OM1 and the recent advances in AI and machine learning in general are to identifying more patients and further driving market penetration for Galafold? Thank you.
Bradley Campbell: Yes, great question. I’ll start but then Jeff can give more color on that that collaboration. I think that machine learning will have a major impact on diagnosing, all different sorts of patients. We’re already starting to see some of that. And but I’m really excited to see the outcome of that out of that partnership, and in particular in Fabry. But again, I think that will be an industry-wide and hopefully disease wide phenomenon. But Jeff maybe, give a little bit of color on what we’re doing with OM1 the partnership and what the intent is there?
Jeff Castelli: Yes. Thanks for the question. So really the approach with OM1 and other similar AI electronic medical record initiatives is to create sort of a medical record fingerprint of Fabry disease so that you know all of the healthcare records or people that have given consent within a health system can have their medical records and symptoms kind of scan by the AI, and you basically flag a bunch of people that very may well have Fabry disease and don’t know it. And then testing could be offered through different programs to those patients on. We’re very excited that we published on the development of the outgrowth algorithm and Fabry it looks like it can do a very good job. And we’re actually just on the cusp here of testing it in a very large academic center here in the States.
And by midyear, we should know how well that did. And we actually could see how many people are opting into potentially getting tested through the health provider. So that in February in particular, we’re really excited about this because with being an X-linked disease when you find patients within a certain health care system potentially, with this type of approach, you could then also help that family find people living around the country around that globe or around the globe. You don’t have to kind of screen every single health care system. We are going to certainly look to see if, it’s successful and valuable to see if that could be used in other systems as well. And this is not only for Fabry, there’s actually been similar programs and initiatives done already for other diseases like Pompeii and that has shown a similar approach works there as well.
Q – Unidentified Analyst: Thank you.
Operator: Thank you. That was your last question. This concludes today’s conference call and have a great day.
